19 research outputs found

    Extending Attribute Grammars to Support Programming-in-the-Large

    Get PDF
    Attribute grammars add specification of static semantic properties to context-free grammars, which in turn describe the syntactic structure of program units. However, context-free grammars cannot express programming-in-the-large features common in modern programming languages, including unordered collections of units, included units and sharing of included units. We present extensions to context-free grammars, and corresponding extensions to attribute grammars, suitable for defining such features. We explain how batch and incremental attribute evaluation algorithms can be adapted to support these extensions, resulting in a uniform approach to intra-unit and inter-unit static semantic analysis and translation of multi-unit programs

    Audit on testosterone therapy in adult males with testosterone deficiency

    Get PDF
    Introduction: Hypogonadism is estimated to affect between 2.1 and 12.8% of the adult male population. Method: A review of 235 patients suffering from hypogonadism was undertaken. Local standards of care were compare to the Endocrine Society Clinical Practice Guideline of 2010 (ESCG). Results: Patients complained of 0, 1-4, 5-8 symptoms suggestive of hypogonadism in 17%, 67% and 16% respectively. 76.5% of the patients had repeatedly low testosterone. 20% suffered from primary hypogonadism. 77% suffered from secondary hypogonadism secondary. Karyotype was obtained in 35% and 5% of the patients suffering from primary and secondary hypogonadism respectively. Patients suffering from secondary hypogonadism had serum TSH (94%), prolactin (92%), cortisol (91%), GH levels (89%) and iron studies (43%) analysed. 77% of patients suffering from secondary hypogonadism had an MRI of the pituitary, with an abnormality reported in 53% of the patients. Prior to starting treatment 7% of the patients were assessed for prostate nodules and PSA was taken in 39% of the patients. Only 33% of the patients had bone mineral density (BMD) taken prior to starting testosterone treatment. Patients were reviewed 3-6 months (35%) and then annually (88%) after treatment was initiated. Conclusion: The study identifies the need for documentation of signs and symptoms. Testosterone levels should be repeated prior to starting treatment. It also highlights the need for karyotyping in patients with primary hypogonadism as well as the need to measure BMD and PSA before and after prescribing testosterone. Patients need review at 3-6months after initiation of testosterone supplementations.peer-reviewe

    Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations

    Get PDF
    Purpose To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. Patients and Methods One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO). The primary end point was overall survival (OS). Results There was no difference in remission rate after two courses between FLAG-Ida + GO and DA + GO (complete remission [CR] + CR with incomplete hematologic recovery 93% v 91%) or in day 60 mortality (4.3% v 4.6%). There was no difference in OS (66% v 63%; P = .41); however, the risk of relapse was lower with FLAG-Ida + GO (24% v 41%; P < .001) and 3-year event-free survival was higher (57% v 45%; P < .001). In patients with an NPM1 mutation (30%), 3-year OS was significantly higher with FLAG-Ida + GO (82% v 64%; P = .005). NPM1 measurable residual disease (MRD) clearance was also greater, with 88% versus 77% becoming MRD-negative in peripheral blood after cycle 2 (P = .02). Three-year OS was also higher in patients with a FLT3 mutation (64% v 54%; P = .047). Fewer transplants were performed in patients receiving FLAG-Ida + GO (238 v 278; P = .02). There was no difference in outcome according to the number of GO doses, although NPM1 MRD clearance was higher with two doses in the DA arm. Patients with core binding factor AML treated with DA and one dose of GO had a 3-year OS of 96% with no survival benefit from FLAG-Ida + GO. Conclusion Overall, FLAG-Ida + GO significantly reduced relapse without improving OS. However, exploratory analyses show that patients with NPM1 and FLT3 mutations had substantial improvements in OS. By contrast, in patients with core binding factor AML, outcomes were excellent with DA + GO with no FLAG-Ida benefit

    Incremental Attribute Evaluation with Applications to Multi-User Language-Based Environments

    Get PDF
    The proposed research addresses three problems associated with performing incremental evaluation of attribute grammars: (1) multiple asynchronous subtree replacements in the parse tree that are initiated by external agents, (2) segmentation of the parse tree according to granularity of access rights with respect to these agents, and (3) distribution of the segments across a reliable network. The research focuses on one exemplary application, distributed multi-user language-based environments, where the parse tree represents a program being developed, the subtree replacements are changes to the program, the external agents are programmers, the granularity of segments corresponds to the modularization of the program, and the nodes of the network are the programmers' workstations
    corecore